Power Law company profile

Kriya Therapeutics

Biotech & Life Sciences · Morrisville, United States · Founded 2019 Unicorn

Innovative gene therapies targeting prevalent chronic diseases

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

100–500

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

18 investors on Kriya Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage

Bluebird Ventures

Narya Capital

Dexcel Pharma

Foresite Capital

Paul Manning

Amplo

Asia Alpha

QVT Financial LP

Series B+ 10 investors entered at this stage

Transhuman Capital

Patient Square Capital

JDRF T1D Fund

Hongkou

CAM Capital

Woodline Partners

Premji Invest

Lightswitch Capital

Alumni Ventures

Peter Thiel

Global footprint

Where Kriya Therapeutics has talent and traffic

AI talent share

1.0% of workforce is AI talent
(2 of 195 staff)

Core AI10.51%

Other AI10.51%

Non-AI workforce19398.97%

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

8.2K monthly visits
across markets

🇺🇸 United States75.6%

🇮🇳 India13.4%

🇬🇧 United Kingdom7.3%

🇪🇸 Spain4.9%

Top 4 markets shown

Patent intelligence

$357k patent portfolio · 9 active families

Estimated portfolio value

$357k

0.02% of valuation · 2185.6× smaller than top peer BioNTech ($780M)

9 active patent families

Where Kriya Therapeutics innovates Molecular biologyNucleic acid sequenceExpression cassettePromoterNucleic acid sequencing

Where Kriya Therapeutics concentrates vs peers

Each axis is a top-10 topic across Kriya Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Kriya Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Kriya Therapeutics appeared as a backer or acquirer, 2022–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Kriya Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount

By stageCount

By periodCount

01 · Deployment strategy vs peers

Where Kriya Therapeutics deploys vs peers

Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

Compare against

02 · Portfolio market map

Kriya Therapeutics's portfolio, mapped.

Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

Stage

Period

3 of 3 deals

Market sentiment

What the market is saying about Kriya Therapeutics

An AI-synthesized read of the highest-engagement posts about Kriya Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kriya Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles